as part of the response to the trc’s calls to action 71-76, sshrc is partnering with the nctr to propose a unique opportunity for short-term funding to support indigenous community-led research and related activities involving community decision-making processes, research and actions regarding residential school sites in canada.

this nctr-sshrc initiative is taking the form of a one-time funding opportunity, the partnership engage grants—residential schools joint initiative (peg rsji). the peg rsji will support projects responding to a community’s need for planning, discussions, archival work or storytelling prior to, or in addition to, excavations or identifications on residential school sites in canada. projects can also focus on ground exploration, identification of sites and remains, repatriation of missing children from residential schools in canada, or mapping and preservation of these sites, as judged appropriate by the community.

the novo nordisk foundation, open philanthropy, and the bill & melinda gates foundation have launched the pandemic antiviral discovery (pad) initiative to catalyze discovery and early development of antiviral medicines for future pandemics. this initiative's first request for proposals (rfp) will focus on henipavirus, a subfamily of paramyxovirus that includes nipah virus - a pathogen with an estimated fatality rate of 40% to 75%. researchers from around the world are encouraged to submit proposals; the application deadline is may 5, 2022. future rfps will be announced on the initiative's website.

please contact jill sherman, international research facilitator for more information at:  intl.research@lakeheadu.ca.

the fy22 defense appropriations act is anticipated to provide funding for the orthotics and prosthetics outcomes research program (oporp) to support research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to service members and military beneficiaries, veterans and other individuals with limb loss and/or limb impairment. the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 oporp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website.

the vision of the oporp is to ensure the highest possible quality of life for our service members, veterans, and beneficiaries through the advancement of knowledge in orthotics and prosthetics-related research. the oporp supports research on outcomes-based best practices through analysis of prosthetic and/or orthotic device options that are currently available, and not on the development of new devices or the improvement of an existing technology. projects involving spinal orthoses, pediatric populations, or analysis of short-term use devices will not be considered for the fy22 oporp.

applications submitted to the fy22 oporp must address one or more of the following strategic goals:

• optimize patient-specific technology prescription for the warfighter/veteran. applications submitted to this goal should focus on identifying optimal (1) devices and device characteristics, (2) human interface with devices, and/or (3) intuitive control systems, all grounded in an understanding of the requirements of patient-specific needs and the capabilities and limitation of available devices.
• optimize patient-specific rehabilitation regimens for the warfighter/veteran. applications submitted to this goal should address the cause and effect of an orthotic or prosthetic device on optimal type, timing, and dosing (e.g. duration, frequency, intensity) of rehabilitation for each individual in the context of each person’s unique requirements and preferences. efforts that also address the impact of provider competencies and patient training on the effectiveness of the rehabilitation regimen, as well as efforts to identify the best approaches to mitigate secondary health deficits, are encouraged.
• support standardized assessment of patient outcomes related to prosthetics and orthotics. applications submitted to this goal should seek to validate function and performance, community integration, and user satisfaction outcomes associated with various device properties and functional abilities. an important objective of this goal is to enhance the understanding of the outcomes that matter most for individuals living with orthotic and prosthetic devices.

funding opportunities-fy21 oporp, congressionally directed medical research programs (cdmrp) (army.mil)

clinical research award – letter of intent due may 4, 2022

independent investigators at all academic levels (or equivalent)

• supports clinical research that evaluates orthoses and/or prostheses using patient-centric outcomes relevant to service members and military beneficiaries, veterans, and other individuals with limb loss and/or impairment.
• supported research is intended to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical or policy decisions.
• • multidisciplinary collaboration among academia, industry, patient advocacy, the military services, the u.s. department of veterans affairs (va), and/or other federal government agencies is highly encouraged.
• applications submitted to the fy22 oporp cra must address at least one of the fy22 oporp strategic goals
• preclinical studies using animals are not allowed.
• clinical trials are not allowed.

the fy22 oporp cra offers two funding levels: funding level 1:

• maximum funding of $350,000 for total costs (direct costs plus indirect costs)

• maximum period of performance is 2 years funding level 2:

• maximum funding of $2,000,000 for total costs (direct costs plus indirect costs)

• maximum period of performance is 4 years

clinical trial award – letter of intent due may 4, 2022

independent investigators at all academic levels (or equivalent)

supports the rapid implementation of clinical trials with the potential to have a significant impact on improving the health and well-being of service members and military beneficiaries, veterans, and other individuals with limb loss and/or limb impairment.

• supports clinical trials that evaluate orthoses and/or prostheses using patient-centric outcomes for the purpose of generating clinically useful evidence to enhance and optimize patient outcomes.

• multidisciplinary collaboration among academia, industry, patient advocacy, the military services, va and/or other federal government agencies is highly encouraged.

• applications submitted to the fy22 oporp cta must address at least one of the fy22 oporp strategic goals.

• preclinical studies using animals are not allowed

the fy22 oporp cta offers two funding levels: funding level 1:

• maximum funding of $350,000 for total costs (direct costs plus indirect costs)

• maximum period of performance is 3 years funding level 2:

• maximum funding of $4,000,000 for total costs (direct costs plus indirect costs)

• maximum period of performance is 4 years

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline. all applications must conform to the final funding opportunity announcements that will be available for downloading from the grants.gov website. the application package containing the required forms for each award mechanism will also be found on grants.gov. a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

submission deadlines are not available until the funding opportunity announcements are released. for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org. for more information about the oporp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp public affairs
301-619-9783
usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil

 please contact jill sherman, international research facilitator for more information at:  intl.research@lakeheadu.ca.

the fy22 defense appropriations act is providing funding for the epilepsy research program (erp) to understand the mechanisms of post-traumatic epilepsy (pte) and associated comorbidities to improve quality of life, especially in service members, veterans, and caregivers.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 erp funding opportunity announcements for the following award mechanisms is posted on the grants.gov website. 

applications submitted to the fy22 erp must address one or more of the following focus areas:

• innovative research:  tools intended to better inform or improve upon pte research and care, which may include the following:

o   strategies that will improve seizure detection, characterization, visualization, or diagnosis

o   development of new models or better characterization of existing etiologically relevant models for pte

• markers and mechanisms:  identifying biomarkers or mechanisms of pte, which may include the following:

o   predictive biomarkers for epileptogenesis (acute and chronic)

o   research into the prevention of epilepsy and/or seizures

• epidemiology: epidemiological characterization of pte following traumatic brain injury (tbi), which may include the following:

o   understanding and improving the quality of life of individuals with pte, their families, and their caregivers

o   predictors of the development of epilepsy

o   outcomes, including latency to and prevention of epilepsy, comorbidities, and mortality

• longitudinal studies: studies of the evolution of pte, which may include the following:

o   understanding and improving quality of life of individuals with pte, their families, and their caregivers

o   treatment and healthcare outcomes research, including quality of care

o   natural history of pte and prognosis

o   comorbidities (e.g., depression, functional deficits, sleep disorders, major illness)

funding opportunities-fy22 erp, congressionally directed medical research programs (cdmrp) (army.mil)

idea development award – letter of intent due may 19, 2022

research partnership award – letter of intent due may 19, 2022

the initiating pi and each named co-pi must be at or above the level of an assistant professor (or equivalent) at the time of the application submission deadline.

o  the pi and each named co-pi can be from any field or discipline, but must demonstrate suitable experience relevant to the proposed research.

supports new or existing collaborative research partnerships between/among investigators to address a research problem or question in a manner that would be unachievable through separate efforts.

o  research must address the short-term and long-term impact on the pte research field, patient care, and/or those living with pte.

o  research must be relevant to military service members, their families, and veterans with pte.

o  the application must demonstrate the study team’s experience in pte research, including expertise in the fields of both tbi and epilepsy.

o  applications must include preliminary and/or published data.

o  employing collaborations with members of the pte lived experience community to optimize research impact is encouraged but not required.

o  clinical trials are not allowed.

o  a letter of intent is required; an invitation to submit a full application is not required.

the maximum allowable funding for the entire period of performance is $1,300,000 for total costs.

o  indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

o  the maximum period of performance is 3 years.

**new for fy22**

virtual post-traumatic epilepsy research center (p-terc) – letter of intent due may 19. 2022

virtual post-traumatic epilepsy research center (virtual p-terc) leadership (director and deputy director)

o must be independent investigators at or above the level of associate professor (or equivalent).

o  must have pte research funding (past and present) and have a record of pte publications in peer-reviewed journals.

 the scientific expertise of the director and deputy director should be complementary and within different disciplines along the epilepsy care spectrum.

the director and deputy director are not required to be located at the same organization.

solicits applications for the virtual p-terc director and deputy director, who will establish the virtual p-terc and lead the center in meeting its overarching goal.

 the overarching goal of the virtual p-terc is to develop successful, highly productive pte researchers in a collaborative research and career development environment to enhance quality and expand quantity of the pte research field.

 the virtual p-terc should be a unique, interactive virtual research center providing intensive mentoring, national networking, collaborations, and a peer group for new pte investigators.

 the virtual p-terc should foster convergent science wherein investigators from different disciplines solve specific problems together and take a cross-disciplinary approach to move the pte field forward.

 the virtual p-terc leadership are expected to catalyze the growth and professional development of the faculty in collaboration with the faculty member’s career guide, assess the progress of the faculty, promote the cross-pollination of different scientific disciplines, and facilitate communication and collaboration among all of the faculty and career guides.

 a letter of intent is required; an invitation to submit a full application is not required.

the maximum allowable funding for the entire period of performance is $1,250,000 for direct costs.

 indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 the maximum period of performance is 4 years.

virtual post-traumatic epilepsy research center faculty award – letter of intent fur may 19, 2022

principal investigator (faculty member)

 independent investigators at all academic levels (or equivalent) may be named by the organization as the pi on the application.

 the pi should be new to the field of pte research as evidenced by only nominal publication and/or funding history in the field.

career guide

 must hold a position at or above the level of an associate professor (or equivalent).

 must be a pte researcher that possesses qualifications, background, and experience in both tbi and epilepsy as well as a track record for mentoring investigators in the field.

the pi and career guide do not need to be located at the same organization.

solicits applications for faculty members to join the virtual p-terc.

 supports an impactful research project with an emphasis on discovery that investigates questions across the pte research spectrum.

 supports the career development of the faculty member to advance and sustain an independent career at the forefront of pte research.

 research must address the short-term and long-term impact on the pte research field, patient care, and/or those living with pte.

 research must be relevant to military service members, their families, and veterans with pte.

 preliminary data are encouraged but not required.

 employing collaborations with members of the pte lived experience community to optimize research impact is encouraged but not required.

 clinical trials are not allowed.

 a letter of intent is required; an invitation to submit a full application is not required.

 the maximum allowable funding for the entire period of performance is $500,000 for direct costs.

 indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 the maximum period of performance is 3 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the erp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca.

the fy22 defense appropriations act provides funding for the ocrp to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.  as directed by the office of the assistant secretary of defense for health affairs, the defense health agency j9, research and development directorate, manages the defense health program research, development, test, and evaluation appropriation.  the managing agent for the anticipated program announcements/funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy22 ocrp funding opportunity announcements for the following award mechanisms are be posted on the grants.gov website. 

applications submitted to the fy22 ocrp must address one or more of the following areas of emphasis:

• understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics and other critical events
• develop novel therapeutic strategies for treatment and prevention
• identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis and prognosis
• identify and implement strategies to improve the survivorship and quality of life
• address health disparities
• address precision medicine 

alternatively, with adequate justification, applications may identify and address another area of importance related to the ovarian cancer. justification must be provided in the application.

funding opportunities-fy22 ocrp, congressionally directed medical research programs (cdmrp), us dod (army.mil)

investigator-initiated research award – preproposal due may 2, 2022

must be an independent investigator at or above the level of assistant professor (or equivalent).

partnering pi option:

• ·     up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award..
• ·    supports high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. 
• ·    impact is an important review criterion.
• ·    preliminary data are required.
• ·    clinical trials are not allowed.
• ·    the maximum allowable funding for the entire period of performance is $600,000 for direct costs.
• ·    maximum funding of $800,000 for direct costs (plus indirect costs) for the partnering pi option.
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·    the maximum period of performance is 4 years.

ovarian cancer academy award – early-career investigator – preproposal due may 2, 2022

must be within 5 years of last postdoctoral research position (ph.d.), clinical fellowship (m.d.), or equivalent as of the full application submission deadline. 

a statement of eligibility is required with the submission of the full application.

• ·    the ocrp ovarian cancer academy is a unique, interactive virtual academy providing intensive mentoring, national networking, collaborations, and a peer group for junior faculty.
• ·    early-career investigators whose ability to commit to conducting ovarian cancer research is limited by minimal resources or lack of resources or other overwhelming obstacles are encouraged to apply.
• ·    a designated mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• ·    a designated mentor may only mentor one early-career investigator.
• ·    the designated mentor is not required to be at the same institution as the early-career investigator.
• ·    preliminary data are required.
• ·    clinical trials are allowed.
• ·    pre-application submission is required; application submission is by invitation only.
• ·    the maximum allowable funding for the entire period of performance is $725,000 for direct costs.
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·    the maximum period of performance is 4 years.

pilot award – preproposal due may 2, 2022

investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the principal investigator (pi) on the application.

• ·    supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward.
• ·    innovation and impact are important review criteria.
• ·    the outcome of research supported by this award should be the generation of robust preliminary data that can be used as a foundation for future research projects; thus, preliminary data are not required but are allowed.
• ·    clinical trials are not allowed.
• ·    pre-application is required and is blinded; application is by invitation only.
• ·    the maximum allowable funding for the entire period of performance is $250,000 for direct costs.
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·    the maximum period of performance is 2 years.

proteogenomics research award – preproposal due may 2, 2022

investigators at the level of postdoctoral fellow or clinical fellow (or equivalent) and above may be named by the organization as the pi on the application.

• ·    supports the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.
• ·    innovation and impact are important review criteria.
• ·    analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.
• ·    clinical trials are not allowed.
• ·    preliminary data are not required but are allowed.
• ·    pre-application submission is required; application submission is by invitation only.
• ·    the maximum allowable funding for the entire period of performance is $250,000 for direct costs.
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
• ·    the maximum period of performance is 2 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the ocrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.army.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

please contact jill sherman, international research facilitator for more information at intl.research@lakeheadu.ca.

recognizing memorial university's obligation to ensure that researchers engage with the northern and indigenous people in a respectful, ethical, and deeply collaborative way in keeping with the memorial university’s policy on research impacting indigenous groups, we are pleased to launch the indigenous and northern relationship development fund.

the purpose of this fund is to help researchers establish new relationships or strengthen existing ones. these relationships are important in order to develop collaborative, co-created research projects based on mutual respect and acknowledgment of the deep understanding and knowledge indigenous and northern people bring to such projects as well as ensuring that the academic research and engagement projects meet the needs of the people and the regions where such research takes place.

applicant guide.

for more information, please contact jill sherman, international research facilitator, at intl.research@lakeheadu.ca.

a partnership between memorial university of newfoundland and labrador, the university of the arctic (uarctic), and yukon university, the purpose of this fund is to support researchers with established relationships and partnerships in the arctic region interested in continuing their research and education programs in the region in keeping with the uarctic values, memorial university’s policy on research impacting indigenous groups and supporting priorities within canada’s arctic and northern policy framework.

applicant guide.

for more information, please contact jill sherman, international research facilitator at intl.research@lakeheadu.ca.